[{"id":"0cfe572f-7934-4703-b8bb-bebef2998a06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04862260","created_at":"2021-04-27T14:52:42.546Z","updated_at":"2024-07-02T16:35:01.875Z","phase":"Phase 1","brief_title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04862260","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" APOA1 • APOC3 • ANGPTL3 • ANGPTL8","pipe":"","alterations":" ","tags":["APOA1 • APOC3 • ANGPTL3 • ANGPTL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Repatha (evolocumab) • atorvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-22"}]